news
New improved BNF and BNFC app launched
The British National Formulary (BNF) and British National Formulary for Children (BNFC) have launched a new, faster, easier to use app...
List view / Grid view
National Institute for Health and Care Excellence (NICE)
news
NICE recommends cabozantinib for advanced renal cell cancer
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabozantinib for some kidney cancer patients
news
NICE recommends Lilly’s Baricitinib (Olumiant) to treat rheumatoid arthritis
Baricitinib is the first JAK inhibitor to be recommended by NICE to treat rheumatoid arthritis in adults who have not responded to conventional therapy…
news
NICE approves AstraZeneca’s COPD drug
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).
news
Kadcyla new deal means NICE positive recommendation in draft guidance
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
news
NICE recommends Lilly’s Olaratumab (Lartruvo) to treat sarcoma
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
news
NICE recommends Janssen’s Crohn’s Disease biological therapy
2 May 2017 | By Niamh Marriott, Junior Editor
NICE has recommended Stelara (ustekinumab) in its final appraisal determination as a treatment option for adult patients with Crohn’s disease...
news
NICE does not recommend Janssen’s multiple myeloma drug
29 March 2017 | By Niamh Marriott, Junior Editor
NICE) has published new draft guidance not recommending daratumumab monotherapy (Darzalex, Janssen) to treat some people with multiple myeloma...
news
Price drops make more cancer drugs routinely available
7 March 2017 | By Steve Bremer, Managing Editor
The National Institute for Health and Care Excellence (NICE) is half way through a review of drugs approved and still available only through the old Cancer Drugs Fund (CDF). In all cases so far where NICE has been able to make recommendations for routine NHS use, companies have reviewed and…
news
NICE does not recommend Merck’s lung cancer drug
2 March 2017 | By Niamh Marriott, Digital Editor
NICE has published draft guidance which does not recommend Keytruda, also known as pembrolizumab, for untreated PD-L1-positive metastatic lung cancer...
article
UPDATE: The Cancer Drugs Fund
1 March 2017 | By Niamh Louise Marriott, Digital Editor
This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).
news
NICE does not recommend AbbVie’s leukaemia drug
16 February 2017 | By Niamh Marriott, Digital Editor
The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range...
news
Pfizer’s breast cancer drug too expensive for NHS
3 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance which does not recommend Pfizer's breast cancer drug palbociclib for routine funding on the NHS...
news
NICE approves former CDF kidney cancer drug for NHS use
12 January 2017 | By Niamh Marriott, Digital Editor
Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma...
news
NICE says Roche’s trastuzumab emtansine too expensive for routine NHS use
29 December 2016 | By Niamh Louise Marriott, Digital Editor
Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should...
